KCNQ2
ENSG00000075043
Target class
Ion channel
Chromosome
20
Approved drugs
5
Clinical candidates (approved and in development)
8
- Approved drugs
- 5
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- Yes
- Target name
- KCNQ2
- Gene name
- Potassium voltage-gated channel subfamily Q member 2
- Gene symbol
- KCNQ2
- Protein name
- Potassium voltage-gated channel subfamily KQT member 2 (KQT-like 2) (Neuroblastoma-specific potassium channel subunit alpha KvLQT2) (Voltage-gated potassium channel subunit Kv7.2)
- Kv7.2
- ENB1
- BFNC
- KCNA11
- HNSPC
- EBN
- EBN1
- Gene biotype
- Protein coding
- Gene family
- Potassium voltage-gated channels
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 15
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 165.96
- Tissue specificity (Gini)
- 0.852
- Tissue specificity (tau)
- 0.936
- KEGG gene identifiers
- hsa:3785
- Protein interaction confidence
- 0.858341
- Protein interaction partners
- 44
- R-HSA-1296072
- R-HSA-445095
- End position
- 63472677
- Start position
- 63400208
- Chromosome
- 20
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Endoplasmic reticulum
- PubMed 10788442
- PubMed 9836639
- Tissue specificity (tau)
- 0.936044
- Expression inequality (Gini)
- 0.852162
Expression in transcripts per million
- Brain - Cerebellum
- 165.96
- Brain - Cerebellar Hemisphere
- 146.51
- Brain - Cortex
- 68.13
- Brain - Frontal Cortex (BA9)
- 64.13
- Brain - Anterior cingulate cortex (BA24)
- 50.14
Expression in transcripts per million
- Brain - Cerebellum165.96
- Brain - Cerebellar Hemisphere146.51
- Brain - Cortex68.13
- Brain - Frontal Cortex (BA9)64.13
- Brain - Anterior cingulate cortex (BA24)50.14
- Brain - Nucleus accumbens (basal ganglia)43.36
- Brain - Caudate (basal ganglia)36.76
- Brain - Hippocampus35.04
- Brain - Amygdala34.71
- Brain - Putamen (basal ganglia)26.18
- Brain - Hypothalamus23.11
- Pituitary14
- Brain - Substantia nigra8.11
- Testis6.46
- Brain - Spinal cord (cervical c-1)3.54
- Colon - Sigmoid0.48
- Pancreas0.18
- Colon - Transverse0.17
- Cells - EBV-transformed lymphocytes0.16
- Prostate0.12
- Esophagus - Muscularis0.11
- Esophagus - Gastroesophageal Junction0.11
- Small Intestine - Terminal Ileum0.1
- Adrenal Gland0.08
- Kidney - Medulla0.08
And 29 more, listed on the interactive page.
- GO:0007268
- GO:0007399
- GO:0071805
- GO:0005886
- GO:0008076
- GO:0005249
- GO:0005515
- GO:0005516
- GO:0022843
- GO:0030506
Related records
Trials (176)
- 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
- 4-aminopyridine for Skin Wound Healing
- 4-Aminopyridine in Episodic Ataxia Type 2
- 4-Aminopyridine to Treat Skin Burns
- 4-aminopyridine Treatment for Nerve Injury
- 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
- 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
- 4-AP Peripheral Nerve Crossover Trial
- 4AP for Carpal Tunnel Syndrome (CTS)
- A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures
- A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
- A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Drugs (17)
- Amifampridine Voltage-gated potassium channel blocker
- Amifampridine phosphate Voltage-gated potassium channel blocker
- Azetukalner
- Dalfampridine Voltage-gated potassium channel blocker
- Dronedarone
- Ezogabine KCNQ (Kv7) potassium channel opener
- Flindokalner Voltage-gated potassium channel subunit Kv7.2 activator
- Flupirtine
- Guanidine Voltage-gated potassium channel blocker
- Guanidine hydrochloride Voltage-gated potassium channel blocker
- Linopirdine
- Nerispirdine Voltage-gated potassium channel blocker
- Pyrithione zinc
- Tedisamil Voltage-gated potassium channel blocker
- Tedisamil sesquifumarate Voltage-gated potassium channel blocker
- Tetrylammonium
- Tetrylammonium bromide